ClinConnect ClinConnect Logo
Search / Trial NCT06112353

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Oct 31, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Laparoscopic Bowel Resection Sugammadex Neostigmine Glycopyrrolate Gi 2

ClinConnect Summary

This clinical trial is investigating two different medications, Sugammadex and Neostigmine with Glycopyrrolate, to see which one helps patients recover better after bowel resection surgery, a common procedure for intestinal diseases. Specifically, the study looks at how quickly patients can have their first bowel movement and start eating solid foods again, which is important for recovery. The trial is currently recruiting participants who are 18 years or older and are undergoing laparoscopic bowel resection surgery using general anesthesia.

To be eligible for the study, participants must be in good health with no severe heart or lung diseases, and they should not have allergies to the medications being tested. Participants can expect to be monitored throughout their recovery and will help researchers understand which medication works better for getting back to normal after surgery. This study aims to improve recovery times and overall patient care following bowel surgeries.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18 or older
  • Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission
  • Exclusion Criteria:
  • Allergy to Rocuronium, Vecuronium, or Sugammadex
  • Bowel resection surgery requiring an ostomy
  • No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality
  • No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin
  • Creatinine Clearance (CrCl) of less than 30
  • Pregnancy
  • Incapable of providing consent or understanding the research project

About University Of California, Irvine

The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.

Locations

Orange, California, United States

Patients applied

0 patients applied

Trial Officials

Robert R Field, MD

Principal Investigator

Associate Clinical Professor

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported